These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 9129015

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Idiotype vaccination following ABMT can stimulate specific anti-idiotype immune responses in patients with B-cell lymphoma.
    Davis TA, Hsu FJ, Caspar CB, van Beckhoven A, Czerwinsk DK, Liles TM, Taidi B, Benike CJ, Engleman EG, Levy R.
    Biol Blood Marrow Transplant; 2001; 7(9):517-22. PubMed ID: 11669219
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients.
    Timmerman JM, Czerwinski DK, Davis TA, Hsu FJ, Benike C, Hao ZM, Taidi B, Rajapaksa R, Caspar CB, Okada CY, van Beckhoven A, Liles TM, Engleman EG, Levy R.
    Blood; 2002 Mar 01; 99(5):1517-26. PubMed ID: 11861263
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy.
    Massaia M, Borrione P, Battaglio S, Mariani S, Beggiato E, Napoli P, Voena C, Bianchi A, Coscia M, Besostri B, Peola S, Stiefel T, Even J, Novero D, Boccadoro M, Pileri A.
    Blood; 1999 Jul 15; 94(2):673-83. PubMed ID: 10397734
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Vaccine strategies in the treatment of low-grade non-Hodgkin lymphoma.
    Koumarianou A, Kountourakis P, Economopoulos T.
    J Steroid Biochem Mol Biol; 2008 Apr 15; 109(3-5):230-2. PubMed ID: 18406604
    [Abstract] [Full Text] [Related]

  • 11. Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: safety and immunogenicity in a phase I clinical study.
    McCormick AA, Reddy S, Reinl SJ, Cameron TI, Czerwinkski DK, Vojdani F, Hanley KM, Garger SJ, White EL, Novak J, Barrett J, Holtz RB, Tusé D, Levy R.
    Proc Natl Acad Sci U S A; 2008 Jul 22; 105(29):10131-6. PubMed ID: 18645180
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma.
    Schuster SJ, Neelapu SS, Gause BL, Janik JE, Muggia FM, Gockerman JP, Winter JN, Flowers CR, Nikcevich DA, Sotomayor EM, McGaughey DS, Jaffe ES, Chong EA, Reynolds CW, Berry DA, Santos CF, Popa MA, McCord AM, Kwak LW.
    J Clin Oncol; 2011 Jul 10; 29(20):2787-94. PubMed ID: 21632504
    [Abstract] [Full Text] [Related]

  • 15. Recombinant, tumour-derived idiotype vaccination for indolent B cell non-Hodgkin's lymphomas: a focus on FavId.
    Hurvitz SA, Timmerman JM.
    Expert Opin Biol Ther; 2005 Jun 10; 5(6):841-52. PubMed ID: 15952914
    [Abstract] [Full Text] [Related]

  • 16. Idiotype vaccines for non-Hodgkin's lymphoma induce polyclonal immune responses that cover mutated tumor idiotypes: comparison of different vaccine formulations.
    Caspar CB, Levy S, Levy R.
    Blood; 1997 Nov 01; 90(9):3699-706. PubMed ID: 9345055
    [Abstract] [Full Text] [Related]

  • 17. Effect of linkage of transduction domain sequences to a lymphoma idiotype DNA vaccine on vaccine effectiveness.
    Ashour AK, Petersen JL, McIlhaney MM, Vose JM, Solheim JC.
    Hybridoma (Larchmt); 2006 Oct 01; 25(5):306-8. PubMed ID: 17044787
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Monoclonal anti-idiotype antibody therapy of B-cell lymphoma: the addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype-negative variant cells.
    Maloney DG, Brown S, Czerwinski DK, Liles TM, Hart SM, Miller RA, Levy R.
    Blood; 1992 Sep 15; 80(6):1502-10. PubMed ID: 1520877
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.